Navigation Links
Catalyst Pharmaceutical Partners Reports Second Quarter 2008 Financial Results
Date:8/15/2008

CORAL GABLES, Fla., Aug. 15 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today reported financial results for the second quarter and six months ended June 30, 2008.

"We continue to progress with our clinical development program for CPP-109," stated Patrick J. McEnany, Catalyst's Chief Executive Officer. "In particular, we are actively enrolling and dosing subjects in our U.S. Phase II clinical trials evaluating CPP-109 as a treatment for cocaine and methamphetamine addiction. We expect to have top-line results from our cocaine trial and our methamphetamine trial in the first quarter of 2009 and the third quarter of 2009, respectively."

"Additionally, we expect to launch other Phase II trials this year in indications which could include binge eating disorder and alcohol dependence. As we previously discussed, it is likely that Catalyst will seek partners for these indications."

Second Quarter 2008 Results

For the quarter ended June 30, 2008, the Company reported a net loss of $2,377,440, or $0.19 per basic and diluted share, compared to a net loss of $1,208,130, or $0.10 per basic and diluted share for the same period in 2007. Second quarter 2008 results included non-cash charges relating to stock-based compensation in the amount of $123,208, compared to $182,233 in the same period in 2007. For the six months ended June 30, 2008, the Company reported a net loss of $3,961,487, or $0.32 loss per basic and diluted share, compared to a net loss of $2,460,208, or $0.20 loss per basic and diluted share, for the same period in 2007. Results for the first six months of 2008 included non-cash charges relating to stock-based compensation in the amount of $386,612, compared to $382,601 in the same period in 2007.

Research and development expenses for the second quarter of 2008 were $1,902,144 compared to $1,002,780 in the second quarter of 2007, including non-cash stock-based compensation of $99,532 and $161,320, respectively. Research and development expenses for the six months ended June 30, 2008 were $2,986,503 compared to $1,815,300 for the first six months of 2007, including non-cash stock-based compensation of $274,088 and $239,713, respectively.

General and administrative expenses for the second quarter of 2008 totaled $561,533 compared to $434,208 in the second quarter of 2007, including non-cash stock-based compensation of $23,676 and $20,913, respectively. General and administrative expenses for the first six months of 2008 totaled $1,201,206 compared to $1,118,834 in the first six months of 2007, including non-cash stock-based compensation of $112,524 and $142,888, respectively.

As a development stage pharmaceutical company, Catalyst has no revenues to-date.

At June 30, 2008, the Company had cash and cash equivalents totaling $13.1 million and no long-term debt. The Company believes that its existing cash and cash equivalents will be sufficient to meet the Company's projected operating requirements through the second quarter of 2009.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for nine patents and four patents pending in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending in more than 30 countries. The Company's initial product candidate is CPP-109, which is Catalyst's version of vigabatrin. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs. For more information about the Company, please visit http://www.catalystpharma.com.

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including the Company's ability to successfully complete those clinical trials required for it to file a new drug application for CPP-109, the Company's ability to complete such trials on a timely basis within the budgets established for such trials, the Company's ability to protect its intellectual property and those other factors described in the Company's Annual Report on Form 10-K for 2007 and the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2008 that the Company has filed with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect the Company. Copies of the Company's filings with the SEC are available from the SEC, may be found on the Company's website or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.

CATALYST PHARMACEUTICAL PARTNERS, INC.

(a development stage company)

CONDENSED STATEMENTS OF OPERATIONS (unaudited)

For the Three Months For the Six Months

Ended June 30, Ended June 30,

2008 2007 2008 2007

Revenues $ - $ - $ - $ -

Operating costs and

expenses:

Research and

development 1,902,144 1,002,780 2,986,503 1,815,300

General and

administrative 561,533 434,208 1,201,206 1,118,834

Total operating

costs and expenses 2,463,677 1,436,988 4,187,709 2,934,134

Loss from operations (2,463,677) (1,436,988) (4,187,709) (2,934,134)

Interest income 86,237 228,858 226,222 473,926

Loss before income

taxes (2,377,440) (1,208,130) (3,961,487) (2,460,208)

Provision for income

taxes - - - -

Net loss $(2,377,440) $(1,208,130)$(3,961,487) $(2,460,208)

Loss per share - basic

and diluted $(0.19) $(0.10) $(0.32) $(0.20)

Weighted average shares

outstanding - basic and

diluted 12,567,226 12,527,564 12,560,085 12,523,210

CATALYST PHARMACEUTICAL PARTNERS, INC.

(a development stage company)

CONDENSED BALANCE SHEETS

June 30, December 31,

2008 2007

(unaudited)

ASSETS

Current Assets:

Cash and cash equivalents $13,084,108 $15,943,896

Interest receivable 24,167 63,709

Prepaid expenses 288,318 524,081

Total current assets 13,396,593 16,531,686

Property and equipment, net 112,694 127,788

Deposits 25,448 20,448

Total assets $13,534,735 $16,679,922

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities:

Accounts payable $181,276 $219,866

Accrued expenses and other liabilities 558,867 83,419

Total current liabilities 740,143 303,285

Accrued expenses and other liabilities,

non-current 48,720 53,880

Total liabilities 788,863 357,165

Total stockholders' equity 12,745,872 16,322,757

Total liabilities and stockholders' equity $13,534,735 $16,679,922


'/>"/>
SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Controlling the size of nanoclusters: First step in making new catalysts
2. Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement
3. IDEXX Laboratories Announces First Customer Deliveries of Catalyst Dx(TM) Chemistry Analyzer and SNAPshot Dx(TM) Analyzer
4. UCT Specialties (Formerly Petrarch) Announces the Release of Their New Product Guides for Silanes, Silicones, Platinum Catalyst and Glass Coatings
5. Experiments reveal unexpected activity of fuel cell catalysts
6. Using catalysts to stamp nanopatterns without ink
7. Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008
8. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
9. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
10. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
11. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... ... February 04, 2016 , ... Shimadzu Scientific ... LC-MS, host live demos and poster sessions, and present on the analysis of ... takes place March 6 to 10 at the Georgia World Congress Center in ...
(Date:2/4/2016)... N.J. , Feb. 4, 2016  CytoSorbents ... immunotherapy leader commercializing its flagship CytoSorb® blood filter ... surgery patients around the world, announced that CEO ... present at the Source Capital Group,s 2016 Disruptive ... update on the company.  Conference ...
(Date:2/4/2016)... ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), ... of targeted antiviral therapies, announced today that it will ... be held February 8-9, 2016, at the Waldorf Astoria ... & Healthcare Conference, taking place in New ... James Sapirstein , Chief Executive Officer of ContraVir, will ...
(Date:2/4/2016)... ... 04, 2016 , ... Franz Inc. , an early ... has been recognized As “ Best in Semantic Web Technology - USA & ... America, it’s our priority to showcase prominent professionals who are excelling in their ...
Breaking Biology Technology:
(Date:1/20/2016)... , Jan. 20, 2016 A market that ... directly benefit from the explosion in genomics knowledge. Learn ... Sound Research. A range of dynamic trends are pushing ... - personalized medicine - pharmacogenomics - pathogen evolution - ... large markets - greater understanding of the role of ...
(Date:1/18/2016)... JOSE, Calif. , Jan. 18, 2016 /PRNewswire/ ... security software that simplifies the use and access ... technology and go-to-market partnership with American Cyber.  ... Cyber brings extensive experience leading transformational C4ISR and ... implementing and integrating the latest proven technology solutions," ...
(Date:1/13/2016)... 13, 2016 ... of the  "India Biometrics Authentication & ... (2015-2020)"  report to their offering.  ... announced the addition of the  "India ... Estimation & Forecast (2015-2020)"  report ...
Breaking Biology News(10 mins):